Tzioufas-AG; Sakarellos-Daitsiotis-M; Sakarellos-C; Moutsopoulos-HM Αντισώματα έναντι συνθετικών πεπτιδικών αναλόγων της καλρετικουλίνης στις αυτοάνοσες ρευματικές παθήσεις Clin- Exp-Immunol. 1993 Mar; 91(3): 437-41 Προηγούμενες μελέτες έχουν δείξει ότι οροί ασθενών με Συστηματικό Ερυθηματώδη Λύκο (ΣΕΛ) περιέχουν αντισώματα κατά μιας πρωτεΐνης που δεσμεύει ασβέστιο, της καλρετικουλίνης (CaR). Στην μελέτη αυτή παρουσιάζονται οι ανοσολογικές ιδιότητες δύο συνθετικών πεπτιδίων τα οποία αντιστοιχούν στο 1-24 και 7-24 αμινοτελικό άκρο της CaR. Τα δύο συνθετικά πεπτίδια παρασκευάσθηκαν στο εργαστήριο Οργανικής Χημείας του Πανεπιστημίου Ιωαννίνων με πεπτιδική σύνθεση στερεάς φάσης κατά Merrifield και η καθαρότητα τους ελέγχθηκε με φάσμα NMR μιας και δύο διαστάσεων. Για την ανίχνευση αντισωμάτων κατά των πεπτιδίων αυτών χρησιμοποιήθηκε μέθοδος ELISA και μέθοδος ανοσοαποτύπωσης κηλίδων (immunodot assay). Εξετάσθηκαν οροί από 33 ασθενείς με ΣΕΛ, 27 με σ. Sjogren, 28 με Ρευματοειδή Αρθρίτιδα (ΡΑ) και 18 με Μικτή Νόσο του Συνδετικού Ιστού (ΜΝΣΙ). Επιπλέον, 69 οροί φυσιολογικών ατόμων χρησιμοποιήθηκαν για την μελέτη ευαισθησίας των μεθόδων. Όλοι οι οροί των αυτοάνοσων ασθενών εξετάσθηκαν με αντίθετη ανοσοηλεκτροφόρηση για την παρουσία αντισωμάτων κατά των κυτταρικών αντιγόνων Ro/SSA, La/SSB, U 1 RNP, Sm, Scl-70 και Jo-1. Βρέθηκε ότι 33% των ασθενών με ΣΕΛ, 40.7% των ασθενών με σ. Sjogren, 25% των ασθενών με ΡΑ, 27.7% των ασθενών με ΜΝΣΙ και 5.8% του φυσιολογικού πληθυσμού, περιέχουν αντισώματα που αντιδρούσαν με τα συνθετικά πεπτίδια. Δεν υπήρξε συσχέτιση των αντισωμάτων αυτών με αλλά γνωστά αυτοαντισώματα. Τα ευρήματα αυτά οδηγούν στο συμπέρασμα ότι τα αντισώματα κατά καλρετικουλίνης δεν περιορίζονται μόνο στον Συστηματικό Ερυθηματώδη Λύκο, αλλά παρατηρούνται και σε άλλες αυτοάνοσες νόσους. Επιπλέον, καταδεικνύουν την χρησιμότητα των συνθετικών πεπτιδίων σαν πηγή αντιγόνων για την μελέτη των αυτοαντισωμάτων.
INTRODUCTION
Autoimmune rheumatic diseases are often associated wilh a variety of auloanlibodies directed against cytoplasmic or nuclear components. Among ihem., ihe Ro/SSA antigen whieh was initially reported by Clark et al. [1] is a eommon target of an autoimmune response in systemic lupus erythemalosus (SLE) and Sjogren's syndrome (SS) [2.3] . The Ro/SSA anligen is composed of at least two immunologically distinct proteins. 60 ;ind 52 kD, non-covalently bound to a family of small RNAs |4.3!.
Lieu ct al. described a 60-kD protein [6] which was thought to be Ihc 60-kD Ro/SSA. Synthetic pepUdcs corresponding to the amino terminal sequence of this protein, as well as the isolated protein, were selectively recognized by anti-Ro/SSA monospecilic sera. In addition, rabbil anli-peptide sera demonstrated a behaviour identical lo the anti-Ro/SSA sera in Western blot, immunolluorescence and RNA precipitation. Thus, il was proposed that a major autoepitope of the 60-kD Ro/SSA resided within the amino terminal region [6] [7] [8] [9] [10] [11] . However, isolation ofa c-DNA encoding the 60-kD protein [11] revealed that this was human calreticulin (CaR) [12] [13] [14] , a calciumbinding protein, which was also cloned [15.I6|.
The groups of Deutscher [17] and Ben-Chetrit [18] , working independently, isolated the 60-kD Ro/SSA clone, which was found lo be completely different from that of CaR. [ 17, 20] . On the other hand. Rokeach et al. [21.22] using c-DNA. encoded the human hotnologue of CaR. It did nol inleraci with the anti-Ro/SSA monospeeific sera, although it was reactive to specificities such as anli-Ro/SSA (and anti-Sm and/or anti-nRNP). It was also found that this protein did not inleraci either via protein-RNA or proteinprotein inleraelion wilh the Ro/SSA RNPs. The discordance of the results with those previously published [6] [7] [8] [9] [10] [11] may be related to the copurification of both the 60-kD Ro/SSA and CaR [21] . Nevertheless, this assumption does not explain the unti-Ro/SSA reactivity of the synthetic peptides corresponding to the amino terminal part of CaR [7.9] .
The present study was designed to investigate if sera from patients with rheumatie diseases recognized CaR. as well as to gain further insight into autoimmunity. We report on both the synthesis and immunological examination of two peptides homologous lo ihe amino terminal of CaR and corresponding to the 1-24 and 7-24 amino acid sequence ofthe protein.
PATIENTS AND METHODS

Patient sera
Thirty-three sera from patients with SLE. 27 with SS, 28 with rheumatoid arthritis (RA). and 18 with mixed connective tissue disease (MCTD) (diagnosis fultilled the criieria previously described [23] [24] [25] [26] ) were submitted to eounter immunoelectro-phoresis. The following specificities of autoantibodies were found: 49 anti-Ro/SSA. 16 anti-Ro/SSA and anti-La/SSB, 13 anti-nRNP. Sixty-nine notmal sera were collected from healthy bank donors.
Peptide synthesis and purification of the CaR analogues
Two peptides composed of residue 1 -24 (SP24) and 7-24 (SPl 8) ofthe amino terminal sequence of CaR Glu'-Pro-Ala-Vat-TyrPhe-Lys^-Glu-Gln-Phe-Leu-Asp-Gly-Asp-Gly-Trp-Thr-SerArg-Trp-lle-Glu-Ser Lys'"" were synthesized.
Solid-phase synthesis ofthe SP24 and SPI8 using NM-Boc-N-(2-chloro-CBz)-L-lysine-PAM resin (1% cross-linked divinylbenzene-styrene, 1-5 g, 0-39 mep/g) anchor bond and N'-t-Boc/benzyl-side chain protection was carried out by standard methods [27] . Amino acid couplings were performed by the dicyclohexylcarbodiimide (DCC)/hydroxybenzotriazole: (HOBT) procedure using a ratio of amino aeid/DCC/HOBT/ resin (3/3/3/1). Deprotection of the N'-l-Boc protecting group was carried oul using trifluoroacetic acid (TFA) followed by diisopropylethylamine for neutraiizatioti. After synthesis, the peptides were cleaved from the resin with anhydrous HF in the presence of anisole and phenol (10% v/v) as scavengers at 0 C for 1 h. The peptides were extracted from the resin with 2 M acetic acid and lyophilized to give 0-85 g of the 24 SP (52'M, yield) and 0-57 g ofthe 18 SF (45% yield).
Purification of the crude peplides was achieved by anion exchange chromatography on diethyl amino eihyl (DEAE) resin, using as eluent gradient of NHi 01 M/H^O. The peptides were homogeneous as determined by thin-layer chromatography in MeOH/CHCI,/27% NH, (2/2/1) (Rf^^^^ = 073. 
Coupling of peptide to carrier protein
Peptide SP24 was coupled with bovine serum albumin (BSA) via a tyrosine residue with bisdiazobenzidine. as described by Scheidtman [28] , The uncoupled peptide and the coupling reagents were removed by dialysis against PBS at 4 C for 2 days.
ELISA
The modified solid phase assay (ELISA) of Engvall & Perlman [29| was applied. The SP18 and SP24 peptide (1 mg/ml) in ethanol (or PBS at pH ca 7 2) was added to the wells (50 /il/well) of Ihe Nunc microplates and incubaied overnight at 4 C. The microplates were washed with PBS-Tween 20 and the remaining binding sites were coated with 0 5% BSA, 15"/. ovalbumin and 0' I "1. Twecn 20 in PBS (blocking buffer) for 2 h. After washing with PBS-Tween 20. diluted sera (1:50) wilh blocking buffer were added to the wells and incubated for 3 h. The plates were washed again (PBS-Tween 20), and goat anti-human IgG (0 5 mg/l ml) conjugated lo alkaline phosphatase (1:1000 in blocking buffer) was added to the wells. Subsequently, the plales were incubaied for 2 h followed by washing and addition ofthe /(-nitrophenol phosphate substrate at 37 C. The enzymatic reaction was terminated with the addition of NaOH 4 N (50 ^1/ welt), and the optical density was measured at 405 nm.
Binding units are reported (Figs 1 and 2 ) without any subtraction of background binding, since normal and patient sera showed very low and almost identical binding levels to BSA and control peptides.
Dot blot
The Towbin technique [30] modified as follows was used. One microlitre ofthe water pepllde solutions (2 mg/mi) was spotted on Immobilon polyvinyledene difluorlde (PVDF) membranes, incubated with bkx:king buffer for 2 hand then with diluted sera (1:50) in blocking buffer at 4 C overnight. After washing with PBS-Tween 20, a solution of goal anti-human IgG eonjugated lo peroxidase was added and allowed to react for 1 h. The membranes were washed and the colour was developed by adding a substrate solution of 4-chloro-l-naphthol.
Counter immunoctectrophore.sis
The method was performed as described by Bunn ei al. [31] , using calf thymus extract as antigen source.
RESULTS
Qualitative analysis of autoanlibodies. against the CaR peptide analogues (SP24. SFISj
The qualitative analysis ofthe autoantibodies directed against the prepared peptides SPI8 and SP24 was performed using Dot blot (Fig. 3) . Normal sera did not recognize any of the synthetic peptides., while sera from human autoimmune patients were found to react selectively with them. In contrast, the control peptides did not demonstrate any antigenic reactivity to either normal or patient sera (Fig. 3) .
Uuigenicity ofthe CaR peptide analogties
Human autoimmune patient sera. The solid-phase assay method (ELISA) was applied for the quantification of anti-SP :intibodies in autoimmune patient sera. Thiriy-three percent of patients with SLE, 40-7% of patients with SS, 25"A> of patients with RA, 27-7% of patients with MCTD and 5-8% of normals were found to be positive for the anti-SP24 antibodies (Fig. 1) .
The same sera, when allowed to interact with the BSA-SP24, exhibited greater binding levels compared with the free SP24 (data not shown), while no binding activity was detected for BSA. Control peptides were inactive to the normal and patient sera.
Human autoantihody specificities. Human autoimmune sera specific for various antigens (Ro/SSA. La/SSB, nRNPs) were tested (ELISA) for quantitative binding reactivity to the SP24 atid SPI8 CaR analogues. Overall. 285% of anti-Ro/SSA sera. 29 4% of anti-Ro/SSA and anti-La/SSB sera and 46 I % of antinRNP sera were positive lo the anti-SP antibodies (Fig. 2) . SLE and SS patients monospecitic for anti-Ro/SSA were positive for the SP24 antibodies in 35'^ and 37-5%. respectively (data not shown). Control peptides did not show any antigenicity to normal and patient sera. The following control peptides were used in all experiments (Figs 1-3 ): (i) Trp-Asn-Pro-Asn-AspTyr-Gly-Gly-lle-Lys; (ii) Trp-Asn-Pro-d-Ala-Asp-Tyr-GlyGly-lle-Lys; (iii) Arg-Leu-Gly-Arg-Leu-Gly; and (iv) Poly (Arg-Nva-Giy).
The immunological activity of both synthetic peptides was approximately the same in all cases, suggesting an identical antigenic determinant in the 1 -24 and 7-24 amino acid sequence in CaR.
DISCL'SSION
Two peptides composed of residues 1-24 (SP24) and 7-24 (SF18) from the amino terminal sequence of CaR were synthesized using solid-phase methodology. The CaR poptide analogues reacted in ELISA with sera from patients with SLE, SS, RA as well as MCTD (Fig. 1) , which in agreement with previous observations suggested that anti-CaR autoantibodies are not restricted to any subset of the disease [7] [8] [9] .
Both the SPI8 and SP24 peptides were positive (ELISA) to specific human sera antibodies, such as anti-Ro/SSA. anti-Ro/ SSA and anti-La/SSB and in some cases with anti-nRNP (Fig. 2) and anti-Sm (not shown in Fig. 2) . However, the coexistence of anti-Ro/SSA autoantibodies with anti-nRNP and anti-Sm can not be excluded, since it is known that the 52-kD-Ro/SSA antibodies and subpopulations of the 60-kD-Ro/SSA antibodies specifically recognize human antigens, but fail to bind non-primate antigen which was used in the counter immunoeleetrophoresis [32.33] .
It is also interesting to note thai Ihe prepared CaR analogues appeared immunoreactive to anti-Ro/SSA autoimtiiune sera (Fig. 2) . although ihe CaR encoded frotn c-DNA did nol exert similar reactivity [21.22] (the encoded CaR interacted to antiRo/SSA (and anti-Sm and/or anti-nRNP sera)). These confliciing findings may be attributed to the additional amino terminal residues of the recombinant CaR, which are absent in the authentic protein [21] , In addition, it is probable ihat this amino acid sequence, rich in hydrophobic residues (signal peptide). may influence Ihe conformationa! mobitily of the N-lerminal portion of the molecule, whieh consequently may affect antibody recognition. On the other hand, we cannot exclude that the synthetic CaR peptide analogues may be more easily recognized in the anli-Ro/SSA auloimmune sera, compared wilh the whole protein, as a consequence of ihe significant degree ofconformational freedom ofthe relatively short synthetic peptide moieties [34] .
Even though CaR is not recognized by monospeeific antiRo/SSA sera, there is tittle doubt that this protein is a human autoantigen [6, 21, 35] . Our results argue in favour of this observation, since antibodies against the synthetic CaR peptide analogues were detected in al! the autoimmune rheumatic diseases (Fig. 1) . il was also proposed ihatCaR is a heat shock/ stress [15] protein and, therefore, may be related to the autoimmune mechanism [36] . From this point of view, it is not surprising that anti-peptide antibodies were delected in autoimmune sera (Fig. 1) .
Taking into consideration the heterogeneous nature as well as the high molecular mass, as determined by gel filtration, ofthe Ro/SSA-RNP particle [37 39] , one eould pose the question whether CaR is a component ofthe ribonucleoprotein complex. Identification and synthesis of CaR epilope(s), as well as determination of their immunological properties, could answer the above question. Moreover, synthetic CaR peptide analogues could help elucidate the controversial observations presented by Rokeach [21] and McCautilVe et al. [8.9.11] and provide more insight into the cellular function(s) of CaR.
